Open access business models

Re: "Will open access work?"1 It is quite untrue to suggest that our report is biased because its funders all have an interest in the existing subscription/license journal publishing model. We deliberately engaged an impartial consultancy to carry out the work in order that the study should be entirely objective – we are perfectly willing to make the anonymized data freely available for others to analyze. And all three organizations have a strong interest in the Open Access model. The Asso

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Re: "Will open access work?"1 It is quite untrue to suggest that our report is biased because its funders all have an interest in the existing subscription/license journal publishing model. We deliberately engaged an impartial consultancy to carry out the work in order that the study should be entirely objective – we are perfectly willing to make the anonymized data freely available for others to analyze. And all three organizations have a strong interest in the Open Access model. The Association of Learned and Professional Society Publishers (ALPSP) has issued its own position statement,2 and is following with great interest the large number of experiments being carried out, by members and others, on different types of Open Access publication.

The AAAS project on Science and Intellectual Property in the Public Interest, which provided support for the study, has as one of its goals, "developing models that facilitate open access to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Sally Morris

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio